Clinical trial · Interventional
Chemotherapy and Radiotherapy for Osteolymphoma
A Prospective Non-randomised Trial of Chemotherapy and Radiotherapy for Osteolymphoma
NCT00141648CI-TRIAL-00002681completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial is intended to determine the results obtained when standard treatment for Non Hodgkin's lymphoma is applied to the disease in a rare subtype which arises in bone. Patients in the study undergo a detailed assessment, then treatment with chemotherapy and radiotherapy, followed by close monitoring.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Osteolymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone. | Drug | — | UNRESOLVED |
| Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- Chemotherapy followed by radiotherapy to begin 3 weeks after the last cycle.
- interventionNames
- Drug: Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.
- Radiation: Radiotherapy
Primary outcomes (1)
- measure
- Overall Survival. The time from registration to the date of death
- timeFrame
- Main analysis when accrual is complete at approx. 10 years.
Secondary outcomes (2)
- measure
- Time to local or regional failure. Measured from registration.
- timeFrame
- Main analysis when accrual is complete at approx. 10 years.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 17 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed non-Hodgkin's lymphoma in a bony site * Limited extraosseous disease * Ann Arbor stage IE * Age \>17 * ECOG performance status \<3 * Expected survival \> 6 months * Patients capable of childbearing are using adequate contraception. * Written informed consent Exclusion Criteria: * Previous radiotherapy * Previous malignancy * Medically unfit to undergo treatment
References
Publications (3)
- BACKGROUNDChristie DR, Gabriel GS, Dear K. Adverse effects of a multicentre system for ethics approval on the progress of a prospective multicentre trial of cancer treatment: how many patients die waiting? Intern Med J. 2007 Oct;37(10):680-6. doi: 10.1111/j.1445-5994.2007.01451.x. PMID 17894765
- RESULTChristie D, Le T, Watling K, Cornes D, O'Brien P, Hitchins R. Quality assurance audit: a prospective non-randomised trial of chemotherapy and radiotherapy for osteolymphoma (TROG 99.04/ALLG LY02). J Med Imaging Radiat Oncol. 2009 Apr;53(2):203-6. doi: 10.1111/j.1754-9485.2009.02054.x. PMID 19527368
- DERIVEDChristie D, Dear K, Le T, Barton M, Wirth A, Porter D, Roos D, Pratt G. Limited chemotherapy and shrinking field radiotherapy for Osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trial. Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1164-70. doi: 10.1016/j.ijrobp.2010.03.036. Epub 2010 Jul 16. PMID 20638196